Atypical targetoid eruption induced by sorafenib in a patient with hepatocellular carcinoma

Atypical targetoid eruption induced by sorafenib in a patient with hepatocellular carcinoma

Bibliographic Details
Main Authors:	Pinar Incel Uysal, Onder Bozdogan, Nuran Alli, Pelin Demirel
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2020-01-01
Series:	Indian Journal of Dermatology
Online Access:	http://www.e-ijd.org/article.asp?issn=0019-5154;year=2020;volume=65;issue=2;spage=158;epage=160;aulast=Uysal

Similar Items

Generalized livedo reticularis like eruption induced Generalized livedo reticularis like eruption induced by trimethoprim/sulfamethoxazole: A case report with by trimethoprim/sulfamethoxazole: A case report with concomitant myelosuppression
by: Pinar Incel Uysal, et al.
Published: (2017-10-01)

Targetoid form of polymorphic eruption of pregnancy: A case report
by: Michal Bohdanowicz, et al.
Published: (2019-10-01)

Polymorphic Eruption of Pregnancy Presented with Targetoid Lesions: A Report of Two Cases
by: Wararat Sirikudta, et al.
Published: (2013-05-01)

Targetoid Hemosiderotic Nevus
by: Kai-Lv Sun, et al.
Published: (2020-06-01)

Targetoid hemosiderotic hemangioma
by: Rameshwar M Gutte, et al.
Published: (2014-01-01)

Recurrent targetoid hemosiderotic hemangioma
by: Seray Külcü Çakmak, et al.
Published: (2015-04-01)

Evaluation of Sorafenib therapy in hepatocellular carcinoma
by: Ana Margarida da Cruz Alves
Published: (2019)

Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
by: Junji Furuse
Published: (2008-11-01)

Sorafenib for the treatment of advanced hepatocellular carcinoma
by: M Connock, et al.
Published: (2010-05-01)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
by: Zhi Zeng, et al.
Published: (2021-07-01)

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
by: Antje Garten, et al.
Published: (2019-08-01)

Targetoid hemosiderotic hemangioma (hobnail hemangioma): A casereport
by: Shamsi Meymandi S, et al.
Published: (2018-02-01)

Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
by: Katharina Pomej, et al.
Published: (2020-10-01)

Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma
by: Sardar Zakariya Imam, et al.
Published: (2020-09-01)

Radiosensitization effect of Sorafenib in hepatocellular carcinoma treatment
by: John Chun-Hao Chen, et al.
Published: (2018)

Cost effectiveness of sorafenib for advanced hepatocellular carcinoma
by: Jung-Chen Ho, et al.
Published: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
by: Yi-Ling Ko, et al.
Published: (2020-04-01)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
by: Khaldoun Almhanna, et al.
Published: (2009-11-01)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
by: Muhammad W. Saif, et al.
Published: (2011-01-01)

Sorafenib, a systemic therapy for hepatocellular carcinoma
by: Nahum Méndez-Sánchez;, et al.
Published: (2008-01-01)

Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib
by: Monika Moser, et al.
Published: (2021-08-01)

Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib
by: Caroline Petersen da Costa Ferreira, et al.

Treatment options after sorafenib failure in patients with hepatocellular carcinoma
by: Imane El Dika, et al.
Published: (2017-12-01)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
by: Imane El Dika, et al.
Published: (2020-10-01)

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma
by: Yi Shi, et al.
Published: (2021-07-01)

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
by: Shunjie Xia, et al.
Published: (2020-01-01)

Exploration of Sorafenib Influences on Gene Expression of Hepatocellular Carcinoma
by: Huancheng Wang, et al.
Published: (2020-10-01)

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
by: Loraine Kay D. Cabral, et al.
Published: (2020-06-01)

Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
by: Ting Sun, et al.
Published: (2017-11-01)

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
by: L. Barbier, et al.
Published: (2011-01-01)

The role of DKK1 in hepatocellular carcinoma treated with sorafenib
by: Chun-Yi Jiang, et al.
Published: (2014)

Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy
by: Reyes, Ryan
Published: (2016)

Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.
by: Sangheun Lee, et al.
Published: (2013-01-01)

Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma
by: Rachel Sally, BA, et al.
Published: (2021-09-01)

Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
by: Alessandro Granito, et al.
Published: (2016-03-01)

Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case
by: Yu V Bisovskaya, et al.
Published: (2014-06-01)

Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
by: Omar Abdel-Rahman, et al.
Published: (2014-03-01)

Exacerbation of psoriasis with pustulation by sorafenib in a patient with metastatic hepatocellular carcinoma
by: Takenobu Ohashi, et al.
Published: (2019-01-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)